Additionally, in HRD breast cancer cell lines and in vivo models, treatment with PARP inhibitors, which increases DSB formation, enhanced STING pathway activation and resulted in the recruitment of immune cells [44]. This evidence concerns the gene STING1 and breast carcinoma.